Home/Pipeline/Undisclosed T Cell Engager

Undisclosed T Cell Engager

Autoimmune Diseases

Discovery/PreclinicalActive (Collaboration)

Key Facts

Indication

Autoimmune Diseases

Phase

Discovery/Preclinical

Status

Active (Collaboration)

Company

Galapagos

About Galapagos

Galapagos is a commercial-stage biotech transitioning from a platform-centric discovery model to a lean, externally-focused business development engine. Its legacy is anchored by the successful JAK1 inhibitor filgotinib (Jyseleca), developed with Gilead, which provides European revenue and royalties. The company's current strategy, under new leadership, involves winding down internal cell therapy to redeploy capital towards acquiring late-stage clinical assets in high-value therapeutic areas like oncology and immunology, as exemplified by its new T cell engager collaboration with Gilead.

View full company profile

Therapeutic Areas

Immunology & Inflammation Oncology

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Gavocabtagene autoleucel	Astellas	Phase 1/2	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active
I&I Portfolio	Third Arc Bio	Pre-clinical	Active
Undisclosed Platform Programs	Zag Bio	Preclinical	Active
E-602	Palleon Pharmaceuticals	IND-Enabling	Active
DIASPOT Platform Expansion	DIAsource ImmunoAssays	Commercial & Development	Active